Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Cost of Product Revenues: $267M in Q2 2026, up 33.6% from a year earlier. That is the highest of the 34 quarters on record here.
Latest, Q2 2026
267
Period ended Jun 30, 2026
Change on a year earlier
+33.6%
200 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Reported in Form 10-K/10-Q (DB).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of Product Revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 267 | +33.6% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 245 | +32.8% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 219 | +24.5% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 207 | +23.6% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 200 | +17.5% | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 185 | +16.2% | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 176 | +16.6% | Form 10-K (2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 168 | +14.1% | Form 10-Q (2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 170 | +18.9% | Form 10-Q (2024-08-09) ↗ |
| Q1 2024 | Mar 31, 2024 | 159 | +7.4% | Form 10-Q (2024-05-10) ↗ |
| Q4 2023 | Dec 31, 2023 | 151 | +19.1% | Form 10-K (2024-02-29) ↗ |
| Q3 2023 | Sep 30, 2023 | 147 | +27.4% | Form 10-Q (2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 143 | +31.3% | Form 10-Q (2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 148 | +43.9% | Form 10-Q (2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 127 | +35.9% | Form 10-K (2023-03-01) ↗ |
| Q3 2022 | Sep 30, 2022 | 115 | +43.4% | Form 10-Q (2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 109 | +44.1% | Form 10-Q (2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 103 | +56.1% | Form 10-Q (2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 93.3 | +35.2% | Form 10-K (2023-03-01) ↗ |
| Q3 2021 | Sep 30, 2021 | 80.5 | +71.6% | Form 10-Q (2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 75.5 | +76.8% | Form 10-Q (2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 65.8 | +58.6% | Form 10-Q (2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 69 | +74.7% | Form 10-K (2023-03-01) ↗ |
| Q3 2020 | Sep 30, 2020 | 46.9 | +17.0% | Form 10-Q (2020-11-06) ↗ |
| Q2 2020 | Jun 30, 2020 | 42.7 | +3.1% | Form 10-Q (2021-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 41.5 | -0.2% | Form 10-Q (2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 39.5 | -2.0% | Form 10-K (2020-03-02) ↗ |
| Q3 2019 | Sep 30, 2019 | 40.1 | +1.5% | Form 10-K (2020-03-02) ↗ |
| Q2 2019 | Jun 30, 2019 | 41.4 | +5.6% | Form 10-K (2020-03-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 41.6 | +6.4% | Form 10-K (2020-03-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 40.3 | – | Form 10-K (2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 39.5 | – | Form 10-K (2020-03-02) ↗ |
| Q2 2018 | Jun 30, 2018 | 39.2 | – | Form 10-K (2020-03-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 39.1 | – | Form 10-K (2020-03-02) ↗ |
Cite this data
StockData. (2026). Natera Cost of Product Revenues ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/db-seg-product-cor
See every metric in the Natera KPI table. Data updated Nov 2, 2026.